Medicare Enrolled
Dr. Ryan Olson, MD
Hematology (Pathology) Physician · Fort Myers, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Olson from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Olson? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Olson
Dr. Ryan Olson is a hematology (pathology) physician in Fort Myers, FL, with 17 years in practice. Based on federal Medicare data, Dr. Olson performed 747,498 Medicare services across 398,752 unique beneficiaries.
Between the years covered by Open Payments, Dr. Olson received a total of $3,184 from 4 pharmaceutical and/or device companies across 4 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology (pathology) physician. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Olson is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice▲ Top 7% volume in FL$ $3,184 industry payments
Medicare Practice Summary
Medicare Utilization ↗747,498
Medicare services
Top 7% in FL for hematology (pathology) physician
398,752
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~43,970 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Comprehensive metabolic blood panel | 175,833 | $10 | $39 |
| Ferritin level test (iron stores) | 56,717 | $13 | $47 |
| Immunoglobulin level test | 56,465 | $9 | $32 |
| Iron level test | 51,048 | $6 | $23 |
| Iron binding capacity test | 31,355 | $9 | $31 |
| Lactate dehydrogenase (enzyme) level | 30,249 | $6 | $22 |
| Vitamin B-12 level test | 28,709 | $15 | $54 |
| Measurement of immunoglobulin light chains | 26,008 | $17 | $50 |
| Protein measurement, serum | 25,533 | $11 | $47 |
| Flow cytometry, additional marker | 22,489 | $19 | $120 |
| Thyroid stimulating hormone (TSH) test | 21,815 | $16 | $62 |
| Transferrin (iron binding protein) level | 19,761 | $12 | $42 |
| Immunologic analysis technique on serum (immunofixation) | 19,697 | $20 | $73 |
| Carcinoembryonic antigen (cea) protein level | 19,672 | $19 | $70 |
| Magnesium level test | 19,062 | $7 | $23 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 16,746 | $20 | $71 |
| Folic acid level test | 15,829 | $14 | $52 |
| PSA test (prostate cancer screening) | 10,683 | $18 | $63 |
| Nephelometry, test method using light | 9,574 | $13 | $41 |
| Uric acid level test | 5,174 | $4 | $16 |
| Phosphate level test | 4,709 | $5 | $17 |
| Vitamin D level test | 4,698 | $29 | $105 |
| Beta-2 microglobulin (protein) level | 4,440 | $16 | $56 |
| Haptoglobin (serum protein) level | 4,344 | $12 | $44 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 3,984 | $20 | $71 |
| Tissue staining for diagnosis, additional | 3,699 | $40 | $141 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 3,444 | $20 | $71 |
| Hepatitis b core antibody measurement | 3,325 | $12 | $41 |
| Basic metabolic blood panel | 3,077 | $8 | $30 |
| Free thyroxine (T4) test | 2,896 | $9 | $30 |
| Detection of infectious agent antibody, quantitative | 2,891 | $15 | $38 |
| Erythropoietin (protein) level | 2,834 | $18 | $64 |
| Special stained specimen slides to examine tissue including interpretation and report | 2,718 | $39 | $134 |
| Cortisol (hormone) measurement, total | 2,450 | $16 | $46 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 2,390 | $10 | $35 |
| Microscopic genetic analysis of tissue, computer-assisted technology, initial procedure, each multiplex procedure | 2,283 | $158 | $562 |
| Complete blood count (CBC) with differential | 1,784 | $8 | $29 |
| C-reactive protein test (inflammation marker) | 1,608 | $5 | $13 |
| Lipid panel (cholesterol and triglycerides) | 1,530 | $13 | $46 |
| Tissue culture for tumor disorders of bone marrow and blood cells | 1,519 | $141 | $430 |
| Tissue pathology examination, moderate complexity | 1,227 | $33 | $134 |
| Alpha-fetoprotein (afp) level, serum | 1,063 | $16 | $56 |
| Bilirubin level, direct | 1,016 | $5 | $19 |
| Flow cytometry technique for dna or cell analysis, first marker | 1,008 | $59 | $206 |
| Thyroid hormone, t3 measurement, free | 993 | $17 | $53 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 993 | $66 | $258 |
| Testosterone (hormone) level, total | 919 | $25 | $85 |
| Hemoglobin A1c test (diabetes monitoring) | 911 | $10 | $32 |
| Targeted genomic sequence analysis panel of dna or combine dna and rna of 51 or greater genes associated with blood and lymphatic system disorders | 860 | $2,858 | $7,299 |
| Blood draw (venipuncture) | 849 | $8 | $9 |
| Tissue staining for diagnosis, initial | 804 | $46 | $172 |
| Chromosome analysis for genetic defects, additional karyotypes, each study | 755 | $33 | $88 |
| Interpretation and report of genetic testing | 752 | $26 | $86 |
| Chromosome analysis for genetic defects, analyze 20-25 cells | 731 | $141 | $427 |
| Blood creatinine level | 681 | $5 | $18 |
| Hemoglobin analysis and measurement, electrophoresis | 673 | $13 | $56 |
| Hepatitis b core antibody (igm) measurement | 673 | $12 | $38 |
| Hepatitis c antibody measurement | 651 | $14 | $48 |
| Preparation of tissue for examination by removing any calcium present | 608 | $10 | $36 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 507 | $18 | $56 |
| Rheumatoid factor level | 506 | $6 | $20 |
| Lipase (fat enzyme) level | 479 | $7 | $23 |
| Preparation of specimen, manual | 468 | $138 | $404 |
| Homocysteine (amino acid) level | 453 | $18 | $57 |
| Amylase (enzyme) level | 434 | $6 | $23 |
| Creatine kinase (cardiac enzyme) level, total | 403 | $6 | $23 |
| Bone marrow, smear interpretation | 368 | $55 | $223 |
| Screening examination of specimen cells, screening and interpretation | 340 | $35 | $114 |
| Molecular pathology procedure; physician interpretation and report | 324 | $37 | $139 |
| Liver function blood test panel | 291 | $8 | $28 |
| Microscopic genetic analysis of tumor, manual | 269 | $53 | $202 |
| Chemical receptor analysis | 206 | $36 | $124 |
| Parathyroid hormone level test | 182 | $40 | $141 |
| Translocation analysis (bcr/abl1) minor breakpoint | 173 | $142 | $410 |
| Translocation analysis (bcr/abl1) other breakpoint | 173 | $210 | $644 |
| Chromosome analysis for genetic defects, additional cells counted, each study | 169 | $26 | $65 |
| Gene analysis (mpl proto-oncogene, thrombopoietin receptor) for detection of common variants | 166 | $145 | $451 |
| Translocation analysis (bcr/abl1) major breakpoint | 165 | $161 | $410 |
| Gene analysis (calreticulin), common variants | 165 | $119 | $365 |
| Gene analysis (janus kinase 2) targeted sequence analysis | 165 | $180 | $556 |
| Stool analysis for blood, by fecal hemoglobin determination by immunoassay | 162 | $15 | $48 |
| Gene analysis (janus kinase 2) variant | 161 | $90 | $275 |
| Thyroxine (thyroid chemical), total | 159 | $7 | $26 |
| Genetic sequencing localization, initial procedure | 142 | $120 | $437 |
| Genetic sequencing localization, each additional procedure | 141 | $91 | $322 |
| Blood potassium level | 118 | $5 | $17 |
| Triglycerides level | 108 | $6 | $22 |
| Glutamyltransferase (liver enzyme) level | 91 | $7 | $25 |
| Kidney function blood test panel | 72 | $9 | $30 |
| Gonadotropin, chorionic (reproductive hormone) level | 67 | $15 | $55 |
| Red blood count automated, with additional calculations | 62 | $5 | $17 |
| Cell examination of specimen, selective cellular enhancement technique | 59 | $53 | $164 |
| Cholesterol level | 55 | $4 | $16 |
| Gonadotropin, chorionic (reproductive hormone) measurement | 53 | $15 | $46 |
| Gonadotropin, follicle stimulating (reproductive hormone) level | 46 | $18 | $62 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 42 | $28 | $117 |
| Prostate cancer screening; prostate specific antigen test (psa) | 38 | $19 | $51 |
| Gonadotropin, luteinizing (reproductive hormone) level | 37 | $18 | $62 |
| Measure of severe acute respiratory syndrome coronavirus 2 (covid-19) antibody | 37 | $41 | $106 |
| Red blood count, automated test | 33 | $4 | $12 |
| Calcium level, total | 31 | $5 | $18 |
| Urea nitrogen level to assess kidney function, quantitative | 31 | $4 | $15 |
| Measurement of total estradiol (hormone) | 30 | $27 | $185 |
| Chromosome analysis for genetic defects, count 5 cells | 23 | $259 | $660 |
| Targeted genomic sequence analysis panel of rna of 51 or greater genes associated with blood and lymphatic system disorders | 17 | $2,861 | $7,299 |
| Reproductive hormone panel (estradiol) | 16 | $55 | $178 |
| Stool analysis for blood to screen for colon tumors | 16 | $4 | $14 |
| Thyroid hormone, t3 measurement, total | 13 | $14 | $43 |
| Urinalysis, manual | 12 | $3 | $11 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 11 | $141 | $543 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$3,184
Total received (2020-2024)
Avg $796/year across 4 years
Top 16% in FL for hematology (pathology) physician
4
Companies
4
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,150 (98.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$34 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$14
2023$17
2022$3,150
2020$3
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
JAZZ PHARMACEUTICALS INC.
$3,150
Dexcom, Inc.
$17
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$14
Veracyte, Inc.
$3
Top 3 companies account for 99.9% of total payments
Associated products mentioned in payments ›
Dexcom G6 Transmitter · VYXEOS · XIFAXAN
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (99%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $0 per 100 Medicare services performed
Geographic Context
Hematology (Pathology) Physicians within 10 mi
3
Per 100K population
0.4
County median income
$73,099
Nearest hospital
LEE MEMORIAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Olson is a mixed practice specialist, with above-average Medicare volume (top 7% in FL), and high industry engagement (consulting-driven, top 16%), with 17 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Olson experienced with comprehensive metabolic blood panel?
Based on Medicare claims data, Dr. Olson performed 175,833 comprehensive metabolic blood panel services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Olson receive payments from pharmaceutical companies?
Yes. Dr. Olson received a total of $3,184 from 4 companies across 4 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Olson's costs compare to other hematology (pathology) physicians in Fort Myers?
Dr. Olson's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Olson) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology (Pathology) Physicians in Fort Myers
Browse hematology (pathology) physicians in Fort Myers ranked by procedure volume and transparency data.
Highest volume
Top Hematology (Pathology) Physicians in FL
Hematology (Pathology) Physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology (Pathology) Physicians in FL
Which FL hematology (pathology) physicians receive the most from drug and device companies.
By company
JAZZ PHARMACEUTICALS INC. Payments to Doctors
See all physicians who received payments from JAZZ PHARMACEUTICALS INC..
By company
Dexcom, Inc. Payments to Doctors
See all physicians who received payments from Dexcom, Inc..
By company
Salix Pharmaceuticals, a division of Bausch Health US, LLC Payments to Doctors
See all physicians who received payments from Salix Pharmaceuticals, a division of Bausch Health US, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology